Mirum Pharmaceuticals’ (MIRM) Buy Rating Reaffirmed at HC Wainwright

Mirum Pharmaceuticals (NASDAQ:MIRM)‘s stock had its “buy” rating restated by analysts at HC Wainwright in a research note issued to investors on Wednesday,Benzinga reports. They currently have a $66.00 price target on the stock. HC Wainwright’s target price points to a potential upside of 42.67% from the company’s previous close. HC Wainwright also issued estimates for Mirum Pharmaceuticals’ Q3 2025 earnings at $0.35 EPS and Q4 2025 earnings at $0.61 EPS.

Several other brokerages have also commented on MIRM. Cantor Fitzgerald upped their price objective on shares of Mirum Pharmaceuticals from $50.00 to $60.00 and gave the stock an “overweight” rating in a report on Thursday, August 8th. Robert W. Baird increased their price target on shares of Mirum Pharmaceuticals from $44.00 to $50.00 and gave the stock an “outperform” rating in a research note on Wednesday. Leerink Partners raised their price objective on shares of Mirum Pharmaceuticals from $47.00 to $49.00 and gave the stock an “outperform” rating in a report on Thursday, October 17th. Evercore ISI upped their target price on Mirum Pharmaceuticals from $62.00 to $66.00 and gave the stock an “outperform” rating in a report on Thursday, August 8th. Finally, Citigroup increased their target price on Mirum Pharmaceuticals from $65.00 to $68.00 and gave the stock a “buy” rating in a research report on Wednesday. Ten analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat.com, Mirum Pharmaceuticals has an average rating of “Buy” and a consensus price target of $57.73.

Mirum Pharmaceuticals Stock Up 5.3 %

NASDAQ MIRM opened at $46.26 on Wednesday. Mirum Pharmaceuticals has a 1 year low of $23.14 and a 1 year high of $48.89. The stock has a market capitalization of $2.21 billion, a PE ratio of -23.55 and a beta of 1.16. The company has a debt-to-equity ratio of 1.34, a current ratio of 3.28 and a quick ratio of 3.09. The business’s 50-day moving average is $39.96 and its 200 day moving average is $35.79.

Mirum Pharmaceuticals (NASDAQ:MIRM) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.30) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.15. The firm had revenue of $90.38 million for the quarter, compared to analyst estimates of $81.99 million. Mirum Pharmaceuticals had a negative return on equity of 40.98% and a negative net margin of 31.69%. The business’s quarterly revenue was up 89.4% compared to the same quarter last year. During the same period last year, the company earned ($0.57) EPS. Sell-side analysts forecast that Mirum Pharmaceuticals will post -1.84 earnings per share for the current year.

Institutional Investors Weigh In On Mirum Pharmaceuticals

Hedge funds have recently added to or reduced their stakes in the stock. Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Mirum Pharmaceuticals by 7.2% during the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 18,641 shares of the company’s stock valued at $448,000 after acquiring an additional 1,246 shares in the last quarter. Russell Investments Group Ltd. increased its stake in Mirum Pharmaceuticals by 11.7% during the 1st quarter. Russell Investments Group Ltd. now owns 17,481 shares of the company’s stock valued at $439,000 after purchasing an additional 1,825 shares in the last quarter. Affinity Asset Advisors LLC raised its holdings in Mirum Pharmaceuticals by 220.0% in the first quarter. Affinity Asset Advisors LLC now owns 160,000 shares of the company’s stock worth $4,019,000 after buying an additional 110,000 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its stake in shares of Mirum Pharmaceuticals by 37.2% in the first quarter. Price T Rowe Associates Inc. MD now owns 1,597,506 shares of the company’s stock worth $40,131,000 after buying an additional 432,824 shares in the last quarter. Finally, Silvercrest Asset Management Group LLC grew its holdings in shares of Mirum Pharmaceuticals by 64.6% during the first quarter. Silvercrest Asset Management Group LLC now owns 162,817 shares of the company’s stock valued at $4,090,000 after buying an additional 63,871 shares during the last quarter.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.